Equity Profile

DNLI

Denali Therapeutics Inc.

Health CareBiotechnology$3.1B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

Denali Therapeutics Inc. Misses Revenue, Stock Down 3.43%

Metric	Actual	Expected	Surprise
EPS	$-0.69	$-0.71	+5.48%
Revenue	—	$2M	—

management commentary, guidance changes, and full analysis available with Pro.

Denali Therapeutics Inc. Misses Revenue, Stock Down 3.43%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.69	$-0.71	+5.48%
Revenue	—	$2M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Denali Therapeutics reported a narrower loss per share than expected, which is a positive sign for investors. However, the company did not generate any revenue, missing the consensus estimate of $2 million. The stock reacted negatively, declining by 3.43%, likely due to the lack of revenue and guidance.

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and expectations are set at a loss of $0.71 this quarter.

$-0.71

Revenue

Revenue figures will provide insight into the company's sales performance, with a consensus estimate of $2 million.

$2M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. With a market cap of $3 billion, its work is particularly relevant as the aging population increases the prevalence of conditions like Alzheimer's and Parkinson's disease.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

In the last quarter, Denali reported an EPS of $-0.73, slightly beating expectations but still reflecting ongoing losses. The stock price fell by nearly 4% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Denali to report a loss this quarter, with revenue figures that could vary widely. The market is cautious given the company's history of losses.

Bull Case

If Denali can exceed revenue expectations and show signs of progress in its drug development pipeline, it could lead to a positive market reaction.

Bear Case

Continued losses and lower-than-expected revenue could further dampen investor sentiment, especially if the company fails to provide clear guidance.

Key Metrics to Watch

EPS

$-0.71

Earnings per share is a key indicator of profitability, and expectations are set at a loss of $0.71 this quarter.

Revenue

$2M

Revenue figures will provide insight into the company's sales performance, with a consensus estimate of $2 million.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Denali's revenue exceed the $2 million consensus estimate?

Revenue performance is critical for assessing the company's market traction and future funding needs.

What updates will management provide on their drug development pipeline?

Progress in clinical trials can significantly influence investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Denali's potential for revenue growth due to its innovative pipeline, which could yield unexpected results.

Supporting Evidence

The options market is pricing a 13.3% move, indicating expectations of significant volatility.

Denali has a history of beating EPS estimates, which could lead to a positive surprise this quarter.

Key Risk

If revenue comes in significantly above $2 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining the company's trajectory amid ongoing losses and investor skepticism.

Bull Confirmed If

Revenue exceeding $2 million and positive updates on drug trials would confirm a bullish outlook.

Bear Confirmed If

If revenue falls below $1 million or there are delays in drug development, it would confirm a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±13.3%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±13.3% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

71.9%

Calls (181K)P/C Ratio: 0.55Puts (20K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations, history suggests a potential average move of around -2.64%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty.

Miss

A miss could lead to a decline, with historical data indicating an average drop of -2.48% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials.
2Any commentary on partnerships or collaborations that could enhance revenue.
3Insights into cost management strategies during ongoing losses.
4Details on market demand for their drug candidates.
5Future guidance on expected revenue growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

FANGReported

Diamondback Energy, Inc.

RecapView

May4

OSISReported

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and expectations are set at a loss of $0.71 this quarter.

$-0.71

Revenue

Revenue figures will provide insight into the company's sales performance, with a consensus estimate of $2 million.

$2M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

In the last quarter, Denali reported an EPS of $-0.73, slightly beating expectations but still reflecting ongoing losses. The stock price fell by nearly 4% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Denali to report a loss this quarter, with revenue figures that could vary widely. The market is cautious given the company's history of losses.

Bull Case

If Denali can exceed revenue expectations and show signs of progress in its drug development pipeline, it could lead to a positive market reaction.

Bear Case

Continued losses and lower-than-expected revenue could further dampen investor sentiment, especially if the company fails to provide clear guidance.

Key Metrics to Watch

EPS

$-0.71

Earnings per share is a key indicator of profitability, and expectations are set at a loss of $0.71 this quarter.

Revenue

$2M

Revenue figures will provide insight into the company's sales performance, with a consensus estimate of $2 million.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Denali's revenue exceed the $2 million consensus estimate?

Revenue performance is critical for assessing the company's market traction and future funding needs.

What updates will management provide on their drug development pipeline?

Progress in clinical trials can significantly influence investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Denali's potential for revenue growth due to its innovative pipeline, which could yield unexpected results.

Supporting Evidence

The options market is pricing a 13.3% move, indicating expectations of significant volatility.

Denali has a history of beating EPS estimates, which could lead to a positive surprise this quarter.

Key Risk

If revenue comes in significantly above $2 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining the company's trajectory amid ongoing losses and investor skepticism.

Bull Confirmed If

Revenue exceeding $2 million and positive updates on drug trials would confirm a bullish outlook.

Bear Confirmed If

If revenue falls below $1 million or there are delays in drug development, it would confirm a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±13.3%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±13.3% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

71.9%

Calls (181K)P/C Ratio: 0.55Puts (20K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations, history suggests a potential average move of around -2.64%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty.

Miss

A miss could lead to a decline, with historical data indicating an average drop of -2.48% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials.
2Any commentary on partnerships or collaborations that could enhance revenue.
3Insights into cost management strategies during ongoing losses.
4Details on market demand for their drug candidates.
5Future guidance on expected revenue growth.